Partial
Partially Aligned
Patient Risk:
Medium
Summary
Indications and mechanism statements are supported, but multiple live-vaccine safety claims are overstated or unsupported by the provided label excerpts (e.g., 'contraindicated', increased risk linkage, immunosuppressive terminology), and several specific opportunistic infection examples and cancer/severity claims are not supported by the provided text.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is used to treat moderate to severe plaque psoriasis.
1.1 Plaque Psoriasis
Cosentyx (secukinumab) is used to treat psoriatic arthritis.
1.2 Psoriatic Arthritis
Cosentyx (secukinumab) is used to treat ankylosing spondylitis.
1.3 Ankylosing Spondylitis
Cosentyx works by blocking the action of interleukin-17A.
12.1 Mechanism of Action (binds IL-17A and inhibits interaction with IL-17 receptor)
Patients taking Cosentyx should not receive live vaccines.
17 Patient Counseling Information (vaccination with live vaccines is not recommended during COSENTYX treatment)
Cosentyx can weaken the immune system.
17 Patient Counseling Information (COSENTYX may lower the ability of their immune system to fight infections)
Immunocompromise can increase the risk of serious infections, including opportunistic infections.
17 Patient Counseling Information (serious infections, including opportunistic infections, may occur)
Unsupported Statements
Live vaccines are contraindicated in patients receiving Cosentyx.
Provided label excerpt states live vaccines are not recommended during treatment, but does not use 'contraindicated' language.
Receiving live vaccines while taking Cosentyx may increase the risk of serious adverse reactions.
The provided excerpt instructs that live vaccines are not recommended; it does not describe increased risk of serious adverse reactions from receiving live vaccines while on Cosentyx.
Cosentyx is an immunosuppressive medication.
The provided excerpt uses language about lowering the ability to fight infections; it does not label Cosentyx as 'immunosuppressive'.
Live vaccines may not be able to stimulate a sufficient immune response in patients taking Cosentyx.
The provided excerpt does not state an immunologic sufficiency rationale.
Insufficient immune response to live vaccines in patients taking Cosentyx may increase the risk of infection.
The provided excerpt does not provide this cause-effect linkage.
Opportunistic infections can include pneumocystis pneumonia.
No specific opportunistic infection examples are provided in the supplied label excerpts.
Opportunistic infections can include tuberculosis.
No specific opportunistic infection examples are provided in the supplied label excerpts.
Opportunistic infections can include herpes simplex virus.
No specific opportunistic infection examples are provided in the supplied label excerpts.
Immunocompromise can increase the risk of cancer.
No cancer risk statement is present in the supplied label excerpts.
Immunocompromise can be severe and even life-threatening.
No statement about severity/life-threatening nature of immunocompromise is present in the supplied label excerpts.
For patients taking Cosentyx, alternative vaccines that are not live attenuated may be recommended.
The provided excerpt only states that live vaccines are not recommended; it does not explicitly recommend non-live/alternative vaccines.
Contradictions
High
AI Statement
Live vaccines are contraindicated in patients receiving Cosentyx.
Label Reference
17 Patient Counseling Information (vaccination with live vaccines is not recommended during COSENTYX treatment)
Important Omissions
No dosing/administration details were evaluated against label (e.g., dosage schedules, administration routes, injection technique specifics).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Overstated 'contraindicated' language and multiple unsupported mechanistic/risk-linkage statements (including specific opportunistic infection examples, cancer, and severity) could mislead safety counseling relative to the provided label excerpt, which only states live vaccines are not recommended and advises communication/monitoring for infections.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Live-vaccine and infection-related claims include overstated or unsupported elements (e.g., 'contraindicated', increased serious adverse reactions linkage, specific opportunistic infection examples, cancer/severity statements) not supported by the provided label excerpts.
Suggested Improvement
Use label-supported wording: state that vaccination with live vaccines is not recommended during Cosentyx treatment and that patients should be advised about possible serious infections (including opportunistic infections) and to contact clinicians for infection symptoms; remove unsupported specific infection examples and any 'immunosuppressive'/'contraindicated' or cancer/severity assertions unless supported by the full label.